Altre lingue Werewolf Therapeutics, Inc.

Azioni

HOWL

US95075A1079

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 01/05/2024			Variaz. 5gg	Var. 1 gen.
6,02 ^USD	-3,53%		-5,79%	+55,96%

23/04	Werewolf Therapeutics, Inc. presenta i primi dati preclinici che evidenziano le molecole IL-10 INDUKINE come potenziale terapia per le malattie infiammatorie intestinali al Meeting Annuale AAI	CI
05/04	Werewolf Therapeutics, Inc. presenta i risultati preclinici che dimostrano gli effetti antitumorali dei farmaci a base di citochine pro-infiammatorie	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting	23/04
Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting	23/04
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting	05/04
Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics	05/04
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting	04/04
Werewolf Therapeutics' Q4 Net Loss Narrows	07/03
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	07/03
Werewolf Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference	06/03
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024	05/03
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook	08/01
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors	04/01
Werewolf Therapeutics, Inc. Appoints Michael Atkins to its Board of Directors	04/01
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference	22/11
North American Morning Briefing : Stocks Seen -2-	15/11
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	14/11
Werewolf Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Sector Update: Health Care Stocks Stronger Late Afternoon	03/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Werewolf Therapeutics, Inc.

Azioni

HOWL

US95075A1079

Altre lingue

Filtri